Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
UCB Developed Brands from Anderlecht, company number BE1017533562, closed financial year 2025 with a result of € 827.1 million after tax. For that financial year UCB Developed Brands recorded revenue of € 1.3 billion and equity of € 867.8 million. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 867.8 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 827.1 million
Profit after tax over the fiscal year.
€ 133
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 792.1 million.
People and assets in 2025
20.7
Average over the fiscal year, from the social balance sheet.
€ 4 million
€ 195,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 115.2 million
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 181 days on average.
€ 83 million
Taxes, VAT and social contributions still to pay.
What happened to UCB Developed Brands?
What happened at UCB Developed Brands in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 827.1 million. Source: NBB ↗
- New establishment in Anderlecht. KBO
- New establishment in Braine-l'Alleud. KBO
- Start of the company according to the CBE. KBO
- Denelle WAYNICK JOHNSON became a director. NBB
- Caroline VANCOILLIE became a director. NBB
In short
Paid € 162 million in corporate taxes since 2025.
Pays suppliers within 181 days on average.
Management
The stake of UCB PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
UCB Developed BrandsBehind UCB Developed Brands are Denelle WAYNICK JOHNSON and Caroline VANCOILLIE. The shares are held by UCB Manufacturing Inc. (100%) and UCB PHARMA (100%).
Directors
According to the 2025 annual accounts
Denelle WAYNICK JOHNSON
Director
since 2024
since 2024
Shareholders
UCB Manufacturing Inc.
100%
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Chemin du Foriest 1
1420 Braine-l'Alleud
Active since 17 December 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →UCB Belgium
U C B
UCB PHARMA same network
€ 4.6 billion revenue · 2025
UCB Fipar
Fondation Emmanuel Janssen
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1017.533.562
- VAT number
- BE 1017.533.562
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB Developed Brands
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 December 2024
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Bemiddeling in en het in de handel brengen van octrooien
Speur- en ontwikkelingswerk op biotechnologisch gebied
Groothandel in farmaceutische en medische artikelen